Log in

4882 Perseus Proteomics, Inc. TSE · Japan

Perseus Proteomics (4882) news

Perseus Proteomics, Inc. is a public biotech or pharmaceutical company listed on TSE under the ticker 4882, recorded under Japan. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Perseus Proteomics news

We have not published a story on Perseus Proteomics yet. When there is news, it will appear here.

Questions about Perseus Proteomics

What is the ticker symbol of Perseus Proteomics?

Perseus Proteomics, Inc. trades under the ticker 4882 on TSE.

Where is Perseus Proteomics listed?

Perseus Proteomics, Inc. is listed on TSE.

Which country or territory is Perseus Proteomics listed under?

Our directory records Perseus Proteomics, Inc. under Japan.

What does Perseus Proteomics do?

Our directory classifies Perseus Proteomics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Perseus Proteomics?

The ISIN recorded for Perseus Proteomics, Inc. is JP3836800007.

Does aibio.space cover Perseus Proteomics?

aibio.space lists Perseus Proteomics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Perseus Proteomics?

Companies in our directory listed in the same country and business area as Perseus Proteomics: Koa Shoji Holdings Co., Mochida Pharmaceutical Co., Nxera Pharma Co., Symbio Pharmaceuticals, Katakura Industries Co., Pharmarise Holdings.

Investor discussion: Perseus Proteomics

Members talk about Perseus Proteomics (4882). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open TSE:4882 on TradingView.

Listing details

Perseus Proteomics, Inc. is a public biotech or pharmaceutical company listed on TSE under the ticker 4882, recorded under Japan. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Perseus Proteomics, Inc.
Ticker
4882
Listing
TSE
Country or territory
Japan
Business scope
Pharmaceuticals: Major
ISIN
JP3836800007
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.